In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

A week after Eli Lilly reported the confirmatory study for its cancer drug Lartruvo had failed to help patients live longer, the FDA is discouraging new patients from getting started on the medicine and urging those already on it to consult with their doctors.

The recommendations comes on the heels of a similar announcement from the EMA.